

Bluecrux Unveils Revolutionary Detailed Capacity Planning Solution to Support Advanced Therapy Manufacturing

Executive Summary

Binocs, a Bluecrux technology dedicated to providing capacity planning and scheduling solutions to the life sciences sector, announces a new feature designed to further support production planning for CGT. With the introduction of detailed capacity planning, Binocs extends its suite of functionality for advanced therapy developers and CDMOs, reasserting itself as the best-equipped software platform for planning CGT manufacturing and treatment slot allocation. Bluecrux will be present at Advanced Therapies Week 2024, booth #735.

Bluecrux, a leader in value chain consulting and technologies, is excited to announce a groundbreaking update to their innovative scheduling and capacity planning software platform, Binocs. This feature release sets a new industry standard for Cell and Gene Therapy manufacturing and propels Binocs to the forefront of must-have solutions to support developers and CDMOs in the ATMP space.

New Binocs Feature Highlights

Unique Differentiator: Move beyond a rough-cut approach to capacity management. Binocs now offers unparalleled granularity in production capacity planning, providing a precise understanding of how many patients can be treated with existing manufacturing resources.

Strategic Decision Impact Analysis: Elevate decision-making with an enhanced understanding of the relationship between strategy and capacity. Binocs helps to identify where investments should be made for maximum efficacy, be it in resources, partnerships or process changes.

Buffer Reduction: Liberate working capacity with streamlined planning. Through extensive collaboration with various CDMOs and therapy developers, Bluecrux estimates that as much as 65% of manufacturing capacity is routinely blocked as buffer for unexpected events. With this new feature, Binocs can now significantly reduce buffers and help to precisely evaluate the risks of various planning scenarios.

Increased Efficiency: Existing clients have already reported a remarkable increase of more than 20% in the number of manufacturing slots made available due to the enhanced capacity planning capabilities introduced to Binocs.

Binocs for Cell and Gene Therapy

Since 2022, Bluecrux has collaborated closely with lighthouse customers, such as AstraZeneca and Lyell Therapeutics, to bring their Binocs technology to the next level in the CGT sector. Grounded in more than a decade's experience of providing market-leading solutions for laboratory scheduling and small scale production to the pharmaceutical industry, Binocs has been further developed to deliver a unique slot allocation system for planning advanced therapy treatments.

Over the course of many product releases, Bluecrux has incrementally accelerated and refocused its engineering efforts across multiple domains, as well as appointing a dedicated CGT solution architect. Combined with the proven scalability of the Binocs technology, Bluecrux is fully equipped to deliver significant efficiencies to CGT clients throughout their development, clinical, and commercial phases. The

optimized Binocs scheduling system allows more patients to be treated with the same capacity—or, alternatively, to identify detailed capacity needs to successfully upscale patient treatments.

Want to learn more?

Members of the Bluecrux team will be available to discuss the full suite of functionality at booth #735.